Marketresearchnews

Friday, 23 July 2021

Americas Cancer Immunotherapy Market Report Growth, Size, Demand, Trends And Forecast 2027

Cancer Immunotherapy is an advanced paradigm in cancer therapeutics. Cancer immunotherapy works by enhancing the patient’s immune system. This is generally accompanied by the administration of synthesized immune proteins. The most common therapeutic areas of cancer immunotherapy are inclusive of breast, prostate, lung cancer, and others. Increasing prevalence of the cancer is one of the major drivers for the market growth during the forecast period. Moreover, growing geriatric population and rising healthcare expenditure, increasing biotech and pharmaceutical sector boosts the market growth. However, lack of awareness and high cost for the services may restrain the market growth.

The Americas cancer immunotherapy market is expected to grow at an approximate CAGR of 10.1% during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/592

Segmentation

The Americas cancer immunotherapy market is segmented on the basis of cancer, therapeutics, and end users.

On the basis of the cancer, the market is segmented into lung cancer, prostate cancer, colorectal cancer, head & neck cancer, and others.

On the basis of the therapeutics, the market is segmented into monoclonal antibodies, immune checkpoint inhibitors, vaccines, non-specific cancer immunotherapies and adjuvants, and others.

On the basis of the end users, the market is segmented into hospitals & clinics, academic institutes, research organization, and others.

Regional Analysis

On regional basis the Americas is divided into North America and Latin America. North America is sub segmented into U.S. and Canada. North America commands for the largest market. The large share is also attributed due to the technologically advanced healthcare market, high prevalence of cancer, increasing development in cancer immunotherapy treatment and rising per capita healthcare expenditure. According to the National Cancer Institute in 2016, an estimated 1,685,210 new cases of cancer were diagnosed in the U.S. and approximately 595,690 people died due to cancer within the region. This is projected to drive the healthcare expenditure for cancer. By 2020, approximately USD 156 billion will invested on the cancer therapeutics and diagnostics.

On the other hand, Latin America is the fastest growing region due to the presence of the developing economies within the region, rising healthcare expenditure along with the huge patient population. Moreover, the presence of huge opportunities within the region fuels the market growth during the forecast period.

Key Players

Some of the major player in the market are Amgen Inc. (U.S.), AstraZeneca (U.K), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cancer-immunotherapy-market-592

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Orthopedic Biomaterial Market 2020 Global Trend, Segmentation And Opportunities - Forecast To 2027

Innovation is the organic strategy to gain the market. Many companies are operating in the market, however, the major companies dominated the major share in the market due to well-developed brand identity. Now-a-days, there is a significant increase in the number of the company offering orthopedic biomaterial. Thus companies are adopting the new strategies to minimize the competition and increase the market. Some major companies are focusing on development of new and advanced products to gain the market share. Whereas, some are has used the technique of acquisition and collaboration to gain the market. There is also growing focus on customizing the material properties of bio-absorbable and composite materials with fillers such as bioactive ceramics.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/415

Some of the key players in orthopedic biomaterial market are: Materion Corporation (US), Carpenter Technology Corporation (US), Ulbrich Stainless Steel & Special Metals, Inc. (US), CeramTec (Germany), Ceradyne (US), Heraeus Medical Components (US), Kyocera Corporation (Japan), Ticona GmbH (Germany), Purac Biomaterials (US), Acumed (US), Amedica Corporation (US), Johnson & Johnson (US), Osteotech, Inc. (US), Cam Bioceramics B.V. (Netherland), Landec Corporation. (US), and many more.

Latest Industry Updates

Being a competitive market, a number of different manufacturer are focusing on the product launch, and acquisition for the market development. Some of the latest development in the market are-

Feb 2016, TEKNIMED, a leader in biomaterial and at the forefront in medical solutions of the future, is present in various countries through a network of 250 distributors across the world, launched new biomaterials & surgical solutions in orthopaedics and spine surgery in India

Orchid Orthopedic Solutions is a worldwide leader of medical device outsourcing services from design and development through finished goods manufacturing. The company manufactures the new and advanced orthopedic biomaterials products to the customers.

Global Orthopedic Biomaterial Market – Overview

Today, orthopedics is still in the search for reliable biomaterial for prosthesis. The biomaterial must have good longevity and other supporting properties in order to maintain low implant failure. The success of an implant depends on many factors. Biomaterial are the natural or synthetic materials origin used for the implants. Many medical implants like dental implants, heart valves and many more are prepared by biomaterials. Biomaterial has find its application in orthopedics. They are used in the various bones transplantation. As biomaterial not cause any immunogenic reaction with the body it makes it as a suitable material for this products. According to the Population Reference Bureau (2016), the number of Americans ages 65 and older was around 46 million which is expected to reach over 98 million by 2060. Increasing geriatric population across the globe has led to increase the incidents of diseases like osteoporosis and arthritis. Beside this increasing age simultaneously increases the possibility of bones problems and injury. Additionally, increasing government support, and increasing healthcare expenditure have fuelled the growth of the market during the forecasted period. Due to lack of time for exercise and poor diet increases the incident of different muscles and bone problems. Race to find the cost-effective alternatives has increases the competition between manufacturers and is the key challenge for them. High cost of the products may slow the growth of the market during the forecast period.

Regional Analysis

Regionally, the global orthopedic biomaterial market is segmented into: America, Europe, Asia Pacific, and the Middle East & Africa.

The Americas holds a significant market share of the global market owing to the presence of huge geriatric population and increasing prevalence of different bones diseases. Additionally, during last few years there is a significant increase in the number of accidents which has also helped in driving the growth of the market. Europe accounts for the second largest market in the globe due to a high patient population, high healthcare expenditure and string government support for research & development. Asia Pacific is expecting the fastest growth for the market owing to the presence of the huge opportunity for the growth of the market. The Middle East & Africa holds the least share in the market owing to the presence of the poor economic conditions Africa. Gulf nations such as Saudi Arabia and the UAE drive the Middle East & African market due to the well-developed healthcare sector and huge per capita income of the people.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/orthopedic-biomaterial-market-415

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Orphan diseases Market Report Growth, Size, Demand, Trends And Forecast 2027

Global orphan diseases market also known as rare disease is growing rapidly. It affects a very small percentage of the global population. Most of the orphan diseases are genetic and is remains throughout the life of the patient. There are no exact number of diseases available but approximately there are about 7000 different rare diseases and disorders throughout the globe. Global orphan diseases market is expected to grow at the average CAGR of 24.9% constantly throughout this period 2015-2022. It is also expected that this market which was US$ 121.6 billion in 2015 will grow to US$ 576.9 billion by 2022.However due to lack of awareness, correct diagnosis, correct treatments and availability of healthcare facilities are inhibiting the growth of the global orphan diseases market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2547

Segments:

Global orphan diseases market has been segmented on the basis of types of diseases which includes autoimmune disorders, genetic disorders, blood disorders, cancer, growth disorder, cardiovascular diseases, neurological disorders, respiratory disorders, digestive disorders, eye disorders and others. On the basis of treatment type it segmented into gene therapy, cell therapy, drug therapy and others. On the basis of end user the market is segmented into hospital and clinics, research laboratory and others.

Regional Analysis of Global Orphan diseases Market:

Considering the global scenario of this market, North American region is believed to be the largest market of the global orphan diseases market. Moreover the European market is also growing and is the second largest market for global orphan diseases. On the other hand, Asia-Pacific’s orphan disease market is expected to grow at a significant rate during the forecasted period. Rest of the World is likely to have a limited but steady growth with respect to this market.

Key Players for Global Orphan diseases Market:

Some of the key players in this market are: Bristol-Myers Squibb Company (US), Novartis AG (Switzerland), CELGENE CORPORATION (US), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Alexion (US), Sanofi (French), Vertex Pharmaceuticals Incorporated (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc (US), AbbVie Inc. (US)

The report of global orphan diseases market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts and key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of different markets segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/orphan-diseases-market-2547

Urinary Tract Infection (UTI) Drugs Market Report Growth, Size, Demand, Trends And Forecast 2027

Urinary tract infection (UTI) is the infection of the lower or upper urinary tract generally due to escherichia coli although other bacteria and fundi may be causative organisms. Symptoms include pain with urination, frequent urination and feeling the need to urinate despite having an empty bladder. Risk factors that may cause UTI include female anatomy, sexual intercourse, diabetes, obesityetc. World Health Organization (WHO) estimates that approximately 50 % of women suffer from UTI at some point of time in their lives resulting in more than 1 million hospitalizations per year. WHO estimates the annual cost of UTI infections treatment to be greater than billion. It has further been stated that 1% of boys and 3-8% of girls are diagnosed with UTI. .

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2540

The Middle East and African urinary tract infection (UTI) drugs market is growing due to factors such as catheter associated UTI, hospital borne infections (nosocomial infections), child birth, old age, obesity, growing health awareness especially about women health etc. However, there remain market constraints such as drug resistance, unmet clinical needs, increasing incidence of chronic diseases etc. Another prominent restrain is the excellent efficacy of present antibiotics specially the quinolones. However the rise of drug resistance has negated this constraint and had opened doors to new drug development as a good strategy for UTI treatment.

Taking all these factors into consideration, the Middle East and Africa UTI drugs market had reached around $ 992.84 million from $ 769 million in 2015 by growing at the CAGR of 4.35%.

Study Objectives Middle East and Africa UTI Drugs Market:

To provide detail analysis of the market structure along with forecast for the next 5 years about various segments and sub segments of the Middle East and African UTI Drugs market.
To provide insights about factors affecting the market growth.
To analyze the market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.
To provide past and estimated future revenue of Middle East and Africa UTI drugs market’s segments and sub-segments.
To provide country level analysis of the market with respect to the current market size and future growth prospect.
To provide country level analysis of the market’s segments which includes by drug class, by clinical indication, by end users and other sub segments.
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies and drawing a competitive landscape of the market
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments taking place globally.

Intended Audience

UTI drugs manufacturers
UTI drugs suppliers
Private research laboratories
Research and development (R&D) companies
Market research and consulting service providers
Government research laboratories
Contract manufacturing organizations

Key Players of Middle East and Africa UTI Drugs Market:

Some of the key players in this market are: Bayer AG, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Cipla Inc., Dr. Reddy’s Laboratories Ltd. and others.

Segments:

Middle East and Africa UTI drugs market has been segmented on the basis of drug class which comprises of quinolones, aminoglycosides, β-lactam, azoles and others. On the basis of clinical indications this market is segmented into urethritis, cystitis, and pyelonephritis. On the basis of end users the market is segmented into hospitals and self-administered.

Regional Analysis of Middle East and Africa UTI Drugs Market:

UAE is the largest market of UTI drugs in Middle East and African UTI drugs market closely followed by Egypt. South Africa ranks high in the agendas of many Indian based pharmaceutical firms. The rest of African market is the fastest growing market of UTI drug since there are huge unmet medical needs.

The report about Middle East and Africa UTI Drugs Market by Market Research Future comprises extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value & volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of different markets segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mea-uti-drugs-market-2540

Global Pharmaceutical Filtration Market 2020 Industry Analysis, Share, Growth, Trends And Forecast 2027

Filtration in pharmaceutical has been used to purify or separate the component and also to maintain the sterile conditions during the process to prevent contamination. Various methods are being used for filtration depends on the component that need to be filtered. Major factors such as increasing growth of pharmaceutical industry and rapid growth in the generic drug production are the main reasons driving the market growth. On the other hand the huge capital required to set up new production facilities and stringent government regulations to legalize the filtration process are expected to limit market growth to a certain extent. Globally, the market is growing rapidly and it is anticipated to show an exponential growth reaching approximately Billion in 2022.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2432

Segments:
The pharmaceutical filtrations market has been segmented on the basis of type of filtrations, product, and their application in pharmaceutical industry. On the basis of type the market has been segmented as air filtration, water filtration, chemical filtrations, Grade filtration (liquid and gas), and absorptive filtrations. Similarly on the basis of product, the market has been segmented into membrane filters, media filters, cartridges and capsule filtration and others. On the basis of application in pharmaceutical industry the filtrations market has again segment into air purification, water purification, sterilization, cell separation, media and buffer filtrations and others.

Regional Analysis of Pharmaceutical filtration devices Market:
Considering the global scenario of the market, Americas region is believed to be the largest market for Pharmaceutical filtration techniques and devices. Moreover the European market is also growing continuously and slowly catching up with the American market. On the other hand, Asia-Pacific market is expected to grow at the fastest pace in the pharmaceutical filtration devices segment during the forecasted period. Middle East & Africa region are likely to have a limited but steady growth in the market.

Key Players for Pharmaceutical filtrations devices Market:
Some of the key players in this market are: GE Healthcare (U.S.), Pall Corporation (U.S.), Parker Hannifin Corporation (U.S.), Sartorius Stedim Biotech S.A. (France), Merck KGaA (Germany), Alfa Laval (Sweden), Graver Technologies, LLC (U.S.), Koch Membrane Systems Inc. (U.S.), and GEA Group (Germany).

The report for Pharmaceutical Filtrations Devices Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions

For More Report Details @ https://www.marketresearchfuture.com/reports/pharmaceutical-filtration-devices-market-2432

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Anti-epilepsy drugs Market 2020: Key Companies Profile, Their Market Share And Growth Insights To 2027

Epilepsy is a chronic disorder that causes unprovoked and recurrent seizures. Epilepsy is the fourth most common neurological disorder and affects people of all ages. The patients are reported to loss or disturbance of consciousness and movements along with sensory or psychiatric disturbances. Increasing prevalence of the epilepsy, rising per capita healthcare expenditure and increasing R&D for the therapeutic procedures of the disease drives the market growth during the forecast period, 2017-2022. According to the World Health Organization in 2017, approximately 50 million people across the globe have epilepsy, making it one of the most common neurological diseases globally. Moreover, it was estimated that nearly 80% of the people with epilepsy live in low- and middle-income countries. Additionally, approval of several late-stage pipeline molecules, advancements in drugs modification and favourable government initiative fuels the market growth. However, side effects related to the therapeutic drugs, increasing generic competition and patent expirations are some of the restrains that for the growth during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2345

The global anti-epilepsy drugs market is growing with the sound pace. According to a recent study report published by the Market Research Future, The global anti-epilepsy drugs market is booming and expected to gain prominence over the forecast period growing rapidly .The market is forecasted to demonstrate a sound growth by 2022, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2022).

Global Anti-Epilepsy Drugs Market - Competitive Analysis

Characterized by the presence of several well-established and small players, the global anti-epilepsy drugs market appears to be highly competitive and fragmented. International players who are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.

Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.

Pfizer Inc. is one of the major players of the global anti-epilepsy drugs market and is headquartered in the U.S. In 2015, the company’s total revenue was about USD 48,851 million and it reached USD 52,824 million in 2016. Such a significant increase in the global sales, enabled the company to invest a huge percentage of their sales into the research and development. In 2016, the company spent 14.9% of its total revenue into the R&D enabling it to improve its product portfolio and launch new product, strengthening its position in the market.

In October 2016, Abbott has collaborated with Celgene and Agios for diagnostic identification of IDH mutations. Celgene has done an agreement with Abbott to develop and commercialize the diagnostic tests.

In November 2016, Novartis acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders.

In August 2017, Sanofi completed the acquisition of Protein Sciences, a vaccines biotechnology company based in Meriden, Connecticut in the United States. This acquisition was followed by the Federal Trade Commission approval, having met all the conditions required for the closing of the transaction.

Pfizer, Inc., Johnson & Johnson, UCB Pharma Ltd., Abbott, GlaxoSmithKline plc, Novartis AG, Sanofi, Shire Pharmaceuticals Limited and Cephalon Inc., are some of the prominent players at the forefront of competition in the Global Anti-epilepsy Drugs Market and are profiled in MRFR Analysis.

Global Anti-epilepsy Drugs Market - Regional Analysis

On the regional backgrounds the Americas leads the global market for anti-epilepsy drugs owing to a well-developed healthcare sector, increasing prevalence of epilepsy and presence of the developed technologies within the region. According to the Centres for Disease Control and Prevention, in 2015, 1.2% of the total U.S. population had active epilepsy. Moreover, it was estimated that the yearly total direct and indirect cost of epilepsy in the U.S. was about USD 15.5 billion. Europe is second in the market due to rising healthcare expenditures, huge patient population and growing healthcare R&D expenses by the government. The Asia Pacific region is the fastest growing region due to the developing economies like India and China which are increasing their healthcare expenditures and have huge patient population. Moreover, favourable government policies within the region fuels the market growth. Middle East and Africa have the least market share, especially due to the presence of poor economies and stringent government policies within the African region.

For More Report Details @ https://www.marketresearchfuture.com/reports/anti-epilepsy-drugs-market-2345

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Cataract Surgery device Market 2020: Key Companies Profile, Their Market Share And Growth Insights To 2027

The globally market for cataract surgery device is growing steadily. Factors that influence the cataract surgery device market are increasing prevalence of cataract surgery, increasing advance technology in cataract surgery device market, increase in the aging population, prevalence of eye disease and many others. Globally the market for cataract surgery device is expected to grow at the rate of about 5.5% from 2016 to 2022.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2115

Market Drivers and Restraints:

The occurrence of cataract is very common in the elderly population. Other causative agents of cataract are trauma and long-time exposure to radiations. The increasing prevalence of cataract among geriatric population all over the world is inducing high demand for efficient surgical devices to perform cataract surgery. The rise in preference for less invasive procedures has created huge opportunities for the manufacturers to introduce high-tech ophthalmic surgical devices, leading to the expansion of the global cataract surgery device market.

The government sector in various countries are focusing on increasing awareness regarding cataract and are undertaking the initiatives to provide low-cost cataract surgeries in underdeveloped regions, which in turn is fueling the growth of the global cataract surgery device market. The rise in adoption of advanced technology in the healthcare sector for improving the diagnostics, surgical and treatment procedures is impacting positively on the expansion of the global cataract surgery device market.

However, the population in underdeveloped regions is still unaware of the benefits of cataract surgery, which is negatively impacting on the growth of the global cataract surgery device market. The low penetration of advanced technology and poor primary healthcare infrastructure in underdeveloped regions and in some areas of developing regions are likely to create hindrance in the growth of the global cataract surgery device market during the forecast period.

Market Segmentation:

The global cataract surgery devices market has been segmented on the basis of device type and end-users. Based on device type, the global cataract surgery device market is segmented into Intraocular lens (IOL), Ophthalmic Viscoelastic Device (OVD), Phacoemulsification Equipment and Femtosecond Laser Equipment. Among these, the intraocular lens (IOL) segment is anticipated to project significant growth in the global cataract surgery device market during the forecast period. Based on end-users, the global cataract surgery device market is segmented into hospitals, clinics, ophthalmology centers and others.

Regional Analysis:

The global cataract surgery device market is segmented into five major regions such as North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. Owing to the rapid incorporation of advanced technology in the healthcare sector and increased healthcare expenditure, the North America region is projecting to be the largest market in the global cataract surgery device market.

The Europe region is the second largest market in the global cataract surgery device market due to the increasing incidences of individual suffering from cataract. The high geriatric population and increasing awareness among the population regarding the benefits of cataract surgery are leading to the fastest growth of the global cataract surgery device market. The lack of awareness and poor primary healthcare infrastructure in the underdeveloped areas are negatively impacting on the growth of the cataract surgery device market in the Middle East and Africa region.

Competitive Analysis:

The rapid technological advancement is facilitating the manufacturers to introduce upgraded surgical devices in the global cataract surgery devices market, which in turn is strengthening the competition among the players of the global cataract surgery device market.

On 17Th July 2018, Amring Pharmaceutical Inc., a generic pharmaceutical company, has announced the launch of its latest product, Biolon OVD (Ophthalmic Viscosurgical Device), which will be used while performing cataract surgery.

The key players in the global cataract surgery device market that are profiled in the report published by MRFR are Alcon, Inc. (the U.S), Abbott Laboratories (the U.S.), Carl Zeiss Meditech AG (Germany), Essilor International S.A. (France), Opcon Corporation (Japan), Allergan, Inc. (the U.S.), Bausch & Lomb, Inc. (the U.S.), NIDEK Co., Ltd. (Japan), STAAR Surgical Company (the U.S.) and others.

For More Report Details @ https://www.marketresearchfuture.com/reports/cataract-surgery-device-market-2115